Bristol Myers Squibb (BMY) Net Income towards Common Stockholders (2009 - 2026)

Bristol Myers Squibb has disclosed Net Income towards Common Stockholders across 18 years of filings, most recently posting $2.7 billion for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 8.81% year-over-year to $2.7 billion; the TTM figure through Mar 2026 stood at $7.3 billion (up 36.58% YoY), while the FY2025 annual figure was $7.1 billion, up 178.99% from the prior year.
• Net Income towards Common Stockholders advanced to $2.7 billion in Q1 2026, from $1.1 billion in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for BMY reached as high as $2.7 billion in Q1 2026 and fell as low as -$11.9 billion in Q1 2024.
• The 5-year median for Net Income towards Common Stockholders is $1.6 billion (2024), against an average of $883.5 million.
• Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders tumbled 625.28% — and 2025, when it soared 1328.95%.
• A 5-year view of Net Income towards Common Stockholders shows it stood at $2.0 billion in 2022, then fell by 15.7% to $1.7 billion in 2023, then slumped by 95.55% to $76.0 million in 2024, then soared by 1328.95% to $1.1 billion in 2025, then soared by 146.69% to $2.7 billion in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $2.7 billion, $1.1 billion, and $2.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.